Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Chang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5144-1736; OpenAlex author ID A5100353136. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Co-author DOI 10.1038/s42003-024-06087-8↗
  2. The Efficacy of REG Proteins as a Diagnostic Biomarker for Pancreatic Cancer: a Meta-Analysis. Co-author DOI 10.7754/clin.lab.2023.220906↗
  3. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer. Co-author DOI 10.3389/fonc.2022.991051↗
  4. Expression of TIGAR and its correlation with clinicopathology, prognosis, and 18F-FDG PET/CT parameters in patients with resectable pancreatic ductal adenocarc… Co-author DOI 10.1097/mnm.0000000000001366↗
  5. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p. Co-author DOI 10.1002/jcp.28884↗
  6. Long non-coding RNA LINC01207 silencing suppresses AGR2 expression to facilitate autophagy and apoptosis of pancreatic cancer cells by sponging miR-143-5p. Co-author DOI 10.1016/j.mce.2019.04.004↗
  7. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. First author DOI 10.1186/s13045-019-0777-7↗
  8. Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. Co-author DOI 10.1097/md.0000000000001008↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mingming Zhang · 2 shared papers, 2019 · strength 0.22
  2. Wenyang Zhou · 2 shared papers, 2019 · strength 0.22
  3. Xianghong Yang · 2 shared papers, 2019 · strength 0.22
  4. Liqun Zhang · 1 shared paper, 2023 · strength 0.19
  5. Song Tao Yang · 1 shared paper, 2021 · strength 0.17
  6. Xiaoming Wang · 1 shared paper, 2021 · strength 0.17
  7. Yvette van Kooyk · 1 shared paper, 2024 · strength 0.16
  8. Manfred Wuhrer · 1 shared paper, 2024 · strength 0.16
  9. Kelly Boelaars · 1 shared paper, 2024 · strength 0.16
  10. Ernesto Rodríguez · 1 shared paper, 2024 · strength 0.16
  11. Elisa Giovannetti · 1 shared paper, 2024 · strength 0.16
  12. David Arthur Tuveson · 1 shared paper, 2024 · strength 0.16
  13. Maarten F. Bijlsma · 1 shared paper, 2024 · strength 0.16
  14. Jiwei Liu · 1 shared paper, 2022 · strength 0.15
  15. Aman Wang · 1 shared paper, 2022 · strength 0.15
  16. Haihua Liu · 1 shared paper, 2022 · strength 0.15
  17. Henan Qin · 1 shared paper, 2022 · strength 0.15
  18. Dong Shang · 1 shared paper, 2022 · strength 0.15
  19. Peiyuan Yin · 1 shared paper, 2022 · strength 0.15
  20. Mengyu Feng · 1 shared paper, 2019 · strength 0.08
  21. Guangbing Xiong · 1 shared paper, 2019 · strength 0.08
  22. Li Zhou · 1 shared paper, 2019 · strength 0.08
  23. Jianwei Xu · 1 shared paper, 2019 · strength 0.08
  24. Gang Yang · 1 shared paper, 2019 · strength 0.08
  25. Fangyu Zhao · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.